Table 2.
Cell death rates of OS-II and OS-III primary osteosarcoma cell cultures
| Treatment | Dead cells (%) | ||
|---|---|---|---|
| OS-II (n = 10) | OS-III (n = 12) | MG-63 | |
| Control | 5.78 ± 1.20 | 5.06 ± 0.96 | 5.23 ± 0.83 |
| Cisplatin (10 nmol/L) | 19.75 ± 3.52†,§,∥,¶ | 11.90 ± 2.23†,§,∥,¶,* | 15.72 ± 1.95 |
| Cisplatin (10 nmol/L) + ET-1 (10 pmol/L) | 10.53 ± 2.09†,‡,∥,#,¶ | 7.22 ± 1.56‡,∥,#,¶ | 7.72 ± 1.32 |
| Cisplatin (10 nmol/L) + ET-1 (100 pmol/L) | 4.16 ± 0.93‡,§,#,¶ | 3.85 ± 0.78‡,§,#,¶ | 4.05 ± 0.61 |
| Cisplatin (10 nmol/L) + ET-1 (100 pmol/L) + BQ123 (100 pmol/L) | 20.44 ± 2.21†,§,∥,¶ | 13.25 ± 2.05†,§,∥,¶,* | 17.86 ± 1.72 |
| Cisplatin (10 nmol/L) + ET-1 (100 pmol/L) + BQ123 (1 μmol/L) | 30.86 ± 4.70†,‡,§,∥,# | 29.72 ± 4.43†,‡,§,∥,#,¶ | 30.05 ± 4.08 |
| Cisplatin (10 nmol/L) + BQ123 (100 pmol/L) | 27.06 ± 3.65†,‡,§,∥,# | 19.33 ± 3.87†,‡,§,∥,#,* | 22.65 ± 3.05 |
| Cisplatin (10 nmol/L) + BQ123 (1 μmol/L) | 32.88 ± 6.47†,‡,§,∥,# | 33.54 ± 7.02†,‡,§,∥,#,¶ | 33.12 ± 6.25 |
| BQ123 (1 μmol/L) | 5.82 ± 1.32‡,§,#,¶ | 5.11 ± 1.13‡,§,#,¶ | 5.25 ± 0.96 |
| BQ788 (1 μmol/L) | 5.75 ± 1.27‡,§,#,¶ | 5.01 ± 1.06‡,§,#,¶ | 5.19 ± 0.89 |
| Cisplatin (10 nmol/L) + ET-1 (100 pmol/L) + BQ788 (1 μmol/L) | 7.02 ± 1.55‡,§,∥,#,¶ | 6.88 ± 1.37‡,§,∥,#,¶ | 6.57 ± 1.12 |
†p < 0.05 compared with control; ‡p < 0.05 compared with cisplatin (10 nmol/L); §p < 0.05 compared with cisplatin (10 nmol/L)+ET-1 (10 pmol/L); ∥p < 0.05 compared with cisplatin (10 nmol/L)+ET-1 (100 pmol/L); #p < 0.05 compared with cisplatin (10 nmol/L)+ET-1 (100 pmol/L)+BQ123 (100 pmol/L); ¶p < 0.05 compared with cisplatin (10 nmol/L) + BQ123 (100 pmol/L); *p < 0.05 compared with the OS-II group; OS-II = Stage II osteosarcoma; OS-III = Stage III osteosarcoma.